|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 219.29. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.56 mL||22.8 mL||45.6 mL|
|5 mM||0.91 mL||4.56 mL||9.12 mL|
|10 mM||0.46 mL||2.28 mL||4.56 mL|
|50 mM||0.09 mL||0.46 mL||0.91 mL|
References are publications that support the products' biological activity.
Engelhardt (1984) Structure activity relationships in further series of amino-halogen substituted phenyl-aminoethanols. Arzneimittelforschung 11A 1625 PMID: 6152155
Strosberg and Pietri-Rouxel (1996) Function and regulation of the β3-adrenoceptor. TiPS 17 373 PMID: 8979772
If you know of a relevant reference for Cimaterol, please let us know.
View Related Products by Product Action
Keywords: Cimaterol, supplier, β-adrenoceptor, beta-adrenoceptors, b-adrenoceptors, agonists, β-adrenergic, beta-adrenergic, b-adrenergic, Receptors, Non-Selective, Non-selective, Adrenergic, Beta, Receptors, Non-selective, Adrenergic, Beta, Receptors, Tocris Bioscience
2 Citations for Cimaterol
Citations are publications that use Tocris products. Selected citations for Cimaterol include:
Mistry et al (2013) Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists. J Med Chem 56 3852 PMID: 23614528
Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685
Do you know of a great paper that uses Cimaterol from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.